Cardiovascular disease and cardiac biomarkers

Optimising cardiometabolic disease management together

Worldwide, over 30% of all deaths are attributable to cardiovascular disease Worldwide, over 30% of all deaths are attributable to cardiovascular disease (CVD).¹ In the UK alone, CVD affects around seven million people and is responsible for one in four premature deaths.² The increasing incidence and high healthcare costs associated with CVDs require a holistic approach to prevention, early detection & treatment and monitoring of disease progression. Used in conjunction with clinical information, cardiac biomarkers are crucial to support an early and accurate diagnosis.^3-6

The importance of diagnostics

Diagnostic tests play a crucial part in healthcare. They account for only a fraction of the total healthcare spending (<2%), while informing ~70% of clinical decisions.⁷

As the global market leader in in vitro diagnostics, Roche continuously invests in evidence generation on new uses of biomarkers to improve cardiometabolic care and outcomes for patients.^8‑10.  In 2023 alone, we invested CHF 13.2 million in research and development and delivered 6 new platforms, 21 diagnostic tests and 7 digital solutions,11 alongside CMD pipeline acceleration through partnerships and acquisitions.¹²

With biomarkers and digital solutions, Roche enables earlier diagnosis, reducing time to discharge, and providing information for personalised treatment plans.^13,14

Our commitment

Roche has been the pioneer in CVD biomarkers, including high-sensitive Troponin T and NT-proBNP, With continuous investment for the past 30 years, we remain committed to optimizing cardiometabolic (CMD) care, and to continue bringing even more accurate diagnostics solutions to market. ^{8-10, 15-17}